



Michael Wonder has been in health economics (pricing and reimbursement) role at Novartis Pharmaceuticals Australia since its formation as a result of the merging of Ciba-Geigy & Sandoz in late 1996.

Michael completed a Bachelor of Science (Honours) degree in Biochemistry & Pathology from the University of Melbourne in 1982 and a Bachelor of Pharmacy degree from the Victorian College of Pharmacy in 1985.

He joined the pharmaceutical industry in 1991 after working for five years as a hospital pharmacist at the Austin Hospital in Melbourne.

First as Health Economics Manager and later as Senior Manager, Reimbursement & Pricing, Michael was responsible for the strategic development and subsequent preparation of approximately ninety reimbursement and/or pricing submissions for new drugs/indications to the Pharmaceutical Benefits Advisory Committee (PBAC) and the Pharmaceutical Benefits Pricing Authority (PBPA). As well, Michael was responsible for negotiation of the prices of new drugs with the PBPA for seven years.

In August 2004, Michael was promoted to the position of Director, Global Pricing and Market Access Operations, Global Pricing and Market Access, Novartis Pharma AG, Basel Switzerland based in Sydney.

In this role, Michael works to ensure that the evidence needs of the major pricing and reimbursement agencies for the company's key development compounds are identified during their early development and built into the clinical development plans before the start of the Phase III clinical trials.